Erschienen in:
Cancer Diagnosis & Prognosis, 2 (2022) 3, Seite 378-383
Sprache:
Nicht zu entscheiden
DOI:
10.21873/cdp.10120
ISSN:
2732-7787
Entstehung:
Anmerkungen:
Beschreibung:
Background/Aim: We previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation analysis of plasma miRNAs to identify miRNAs specific for PBCs. Patients and Methods: Plasma was collected from 80 patients with pancreatic cancer (PC); 18 with biliary tract cancer (BTC) and 28 with BD. Sequences encoding 3 tumor suppressive miRNAs (miR-200a, -200b, and -1247) were PCR amplified and sequenced, and their methylation rates were determined. Results: The methylation rate of miR-1247 was significantly higher in patients with BTC than in those with BD, and tended to be higher in patients with PC than in those with BD. Furthermore, it was significantly higher in three patients with stages I/II BTC than in those with BD. Conclusion: Methylation of miR-1247 in plasma may be useful to distinguish BTC from BD.